BeiGene(SH:688235) Xin Lang Cai Jing·2025-08-21 02:15Group 1 - The core viewpoint of the news highlights the strong performance of the biotech sector in the STAR Market, with the STAR Biomedicine Index rising by 1.39% and individual stocks like CanSino and Huaxi Bio showing significant gains [1] - In 2024, the retail pharmacy (DTP) innovative drug sales are projected to reach 88.7 billion yuan, marking a year-on-year growth of 16.6%, while the first quarter of 2025 is expected to see sales of 23.3 billion yuan, a 15.0% increase [1] - The innovative drug sector continues to maintain double-digit growth, significantly outpacing the growth of tiered hospitals, indicating a qualitative leap in channel value [1] Group 2 - According to Shenwan Hongyuan, the innovative drug sector has experienced rapid growth in product revenue and external licensing over the past three years, with significant BD transactions this year driving a trend of expansion across the overall sector [1] - The adjustment of the medical insurance catalog will include commercial insurance for innovative drugs for the first time, which is expected to further support the sector [1] - The STAR Biomedicine ETF closely tracks the STAR Biomedicine Index, which consists of 50 large-cap companies in the biomedicine and related fields, reflecting the overall performance of representative companies in the sector [2]